Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
4 hedge funds and large institutions have $11.2M invested in Cyteir Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 35 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
71% less capital invested
Capital invested by funds: $38.9M → $11.2M (-$27.7M)
89% less funds holding
Funds holding: 38 → 4 (-34)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.25M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$81.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$9.19M |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
-$3.37M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$3.33M |
| 4 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
-$3.12M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.09M |
CYT Hedge Fund Activity: Q1 2024 in Review
4 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2024, worth a combined $11.2M — down 71% from $38.9M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CYT and 1 opened new positions — a net loss of 34 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was BML Capital Management, adding an estimated $1.25M. The largest seller was Newtyn Management, exiting entirely with an estimated $9.19M sold.
- 4 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2024, down from 38 in Q4 2023.
- Funds reported $11.2M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2024, down 71% quarter-over-quarter.
- 1 fund opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2024 and 35 closed out, a net change of -34 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2024 was BML Capital Management, an estimated $1.25M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2024 was Newtyn Management, an estimated $9.19M sold.
Based on aggregated 13F filings for Q1 2024.